As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada
This article was originally published in PharmAsia News
Executive Summary
The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.